Contact Us (781) 301-7474

Investors

Hemanext has committed its resources to the continuing effort of the transfusion medicine community to save lives and improve patient outcomes. The company is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy.

Resources

View Investor Portal for confidential information and updates. Learn about Hemanext ONE technology.

Investment Opportunities

New Investor? Click to Sign-up

Hemanext ONE®

News Updates

Hemanext Partners with Sickle Cell 101 to Sponsor Sickle Cell Education

Hemanext Inc. a privately held, US-based medical technology company dedicated to improving the quality, safety, efficacy, and cost of red blood cell (RBC) transfusions, has partnered with Sickle Cell 101 (SC101), a Silicon Valley-based non-profit, to sponsor and promote sickle cell disease (SCD) education.

Additional Information

Curated resources for news, contact information, and newsletter sign-up.

Privacy


We use cookies to understand how you use our site and to improve your experience. This includes personalizing content. To learn more, click here.